Abuse deterrent compositions and methods of use

1. An orally administrable pharmaceutical composition in unit dosage form comprising:

a barrier layer comprising a barrier polymer comprising a copolymer of ethyl acrylate and methyl methacrylate;

a diffusion layer covering the barrier layer and comprising a drug selected from the group consisting of oxycodone and pharmaceutically acceptable salts thereof, and a diffusion polymer comprising a copolymer of ethyl acrylate and methyl methacrylate; and

an outer coating covering the diffusion layer and comprising a pH-independent agent comprising ethyl cellulose and a pH-dependent agent comprising a cationic polymer comprising dimethylaminoethyl methacrylate, wherein the unit dosage is a tablet, wherein the outer coating does not comprise a drug, wherein the pharmaceutical composition does not comprise an opioid antagonist, mucous membrane irritant, or emetic, wherein the weight ratio of pH-dependent agent to pH-independent agent is about 10:1 to 10:6, and wherein the composition is such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, a sum of the area under the curve (AUC) of the drug and the AUC of a major metabolite of the drug after a period of time is less than the sum of the AUC of the drug and the AUC of the major metabolite achieved after the same period of time after oral administration of the pharmaceutical composition in intact forms; and wherein said cationic polymer with a dimethylaminoethyl group is poly (butylmethacrylate-co-(2-dimethylaminoethyl) methacrylate co-methyl methacrylate.

2. The orally administrable pharmaceutical composition of claim 1 , wherein the composition is such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, the sum of the area under the curve (AUC) of the drug and the AUC of a major metabolite of the drug after a period of time is at least 10% lower than the sum of the AUC of the drug and the AUC of the major metabolite achieved after the same period of time after oral administration of the pharmaceutical composition in an intact form.

3. The orally administrable pharmaceutical composition of claim 1 , wherein the composition is such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, the sum of the area under the curve (AUC) of the drug and the AUC of a major metabolite of the drug after a period of time is at least 20% lower than the sum of the AUC of the drug and the AUC of the major metabolite achieved after the same period of time after oral administration of the pharmaceutical composition in intact form.

4. The orally administrable pharmaceutical composition of claim 1 , wherein the period of time is selected from the group consisting of 0.5 hour, 1 hour, and 2 hours.

5. The orally administrable pharmaceutical composition of claim 1 , wherein the composition is such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, the sum of the AUC 0-t of the drug and the AUC 0-t of a major metabolite of the drug after a period of time is at least 35% lower than the sum of the AUC 0-t of the drug and the AUC 0-t of the major metabolite achieved after the same period of time after oral administration of the pharmaceutical composition in intact form.

6. The orally administrable pharmaceutical composition of claim 1 , wherein the composition is such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, the sum of the AUC 0-t of the drug and the AUC 0-t of a major metabolite of the drug after a period of tira e is at least 40% lower than the sum of the AUC 0-t of the drug and the AUC 0-t of the major metabolite achieved after the same period of time after oral administration of the pharmaceutical composition in intact form.

7. The orally administrable pharmaceutical composition of claim 1 , wherein the composition is such that about 60% or more o the total amount of drug in the pharmaceutical composition is released after 60 minutes under the following dissolution conditions: 0.1 N HCl, 500 mL, USP Apparatus 2 (paddle), 50 rpm, 37° C., and wherein about 25% or less of the total amount of the drug in the pharmaceutical composition is released after 60 minutes under the following dissolution conditions: DI water, 500 mL, USP Apparatus 2 (Paddle), 50 rpm, 37° C.

8. The orally administrable pharmaceutical composition of claim 1 , wherein the composition is such that no more than 50% of the total amount of drug in the pharmaceutical composition is released within 1 hour and about 50% or more of the total amount of drug in the pharmaceutical composition is released after 8 hours under the following dissolution conditons: 0.1 HCl, 500 mL, USP Apparatus 2 (paddle), 50 rpm, 37° C.; and wherein about 25% or less of the total amount of drug in the pharmaceutical composition is released after 60 minutes under the following dissolution conditions: DI water, 500 mL, USP Apparatus 2 (Paddle), 50 rpm, 37° C.

9. The orally administrable pharmaceutical composition of claim 1 , wherein the drug is oxycodone hydrochloride.

10. An orally administrable pharmaceutical composition in unit dosage form comprising:

a barrier layer comprising a barrier polymer comprising a copolymer of ethyl acrylate and methyl methacrylate;

a diffusion layer covering the barrier layer and comprising a drug selected from the group consisting of oxycodone or pharmaceutically acceptable salts thereof, and a diffusion polymer comprising a copolymer of ethyl acrylate and methyl methacrylate; and

an outer coating covering the diffusion layer and comprising a pH-independent agent comprising ethylcellulose, and a pH-dependent agent comprising a cationic polymer comprising dimethylaminoethyl methacrylate, wherein the unit dosage form is a tablet, wherein the pharmaceutical composition does not comprise an opioid antagonist, mucous membrane irritant, or emetic, wherein the weight ratio of pH-dependent agent to pH-independent agent is about 10:1 to 10:6, wherein the outer coating does not comprise a drug and wherein the composition is configured such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, a ratio of the area under the curve (AUC) of the drug to the AUC of a major metabolite of the drug (drug major metabolite) achieved after a period of time is about 10 or less; and wherein said cationic polymer with a dimethylaminoethyl group is poly (butyl methacrylate-co-(2-dimethylaminethyl) methacrylate-co-methyl methacrylate.

11. The orally administrable pharmaceutical composition of claim 10 , wherein the composition is such that when the pharmaceutical composition is administered intranasally in crushed form to a subject, the ratio of the AUC 0-t of the drug to the AUC 0-t of a major metabolite of the drug (drug major metabolite) achieved after a period of time is about 0.1 to about 4.

12. The orally administrable pharmaceutical composition of claim 10 , wherein the drug is oxycodone hydrochloride.

13. The orally administrable composition of claim 10 , wherein the composition is such that about 60% or more of the total amount of drug in the pharmaceutical composition is released after 60 minutes under the following dissolution conditions: 0.1 N HCl, 500 mL, USP Apparatus 2 (paddle), 50 rpm, 37° C.; and wherein about 25% or less of the total amount of drug in the pharmaceutical composition is released after 60 minutes under the following dissolution conditions: DI water, 500 mL, USP Apparatus 2 Paddle), 50 rpm, 37° C.

14. The orally administrable composition of claim 10 , wherein the composition is such that no more than 50% of the total amount of drug in the pharmaceutical composition is released within 1 hour and about 50% or more of the total mount of drug in the pharmaceutical composition is released after 8 hours under the following dissolution conditions: 0.1 N HCl, 500 mL, USP Apparatus 2 (paddle), 50 rpm, 37° C.; and wherein about 25% or less of the total amount of drug is released after 60 minutes under the following dissolution conditions: DI water, 500 mL, USP Apparatus 2 (Paddle), 50 rpm, 37° C.

15. The orally administrable composition of claim 1 , wherein the weight ratio of pH-dependent agent to pH-independent agent is about 10:2 to 10:4.

16. The orally administrable composition of claim 10 , wherein the weight ratio of pH-dependent agent to pH-independent agent is about 10:2 to 10:4.

17. The orally administrable composition of claim 1 , wherein the pH-independent agent comprises ethylcellulose polymer having a viscosity of about 41-49.

18. The orally administrable composition of claim 10 , wherein the pH-independent agent comprises an ethylcellulose polymer having a viscosity of 41-49.

19. The orally administrable composition of claim 1 , which further comprises a filler, glidant, surfactant, lubricant and plasticizer.

20. The orally administrable composition of claim 10 , which further comprises a filler, glidant, surfactant, lubricant and plasticizer.